Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2430-2431, 1997;
This Article
Right arrow Full Text
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banfi, G.
Right arrow Articles by Pontillo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banfi, G.
Right arrow Articles by Pontillo, M.
Related Collections
Right arrow Laboratory Management
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1997;43:2430-2431.)
© 1997 American Association for Clinical Chemistry, Inc.

Technical Briefs

Stability of Tumor Markers CA 19.9, CA 125, and CA 15.3 in Serum Obtained from Plain Tubes and Tubes Containing Thixotropic Gel Separator

Giuseppe Banfia, Pierangela Parma and Marina Pontillo

a author for correspondence: fax + 39 2 2643 2640

The group of tumor-associated antigens with superficial carbohydrate structure influencing cell–cell interaction processes and cell growth regulation is commonly named "mucins," characterized by large and heterogeneic molecular mass and the presence of O-linked carbohydrates. Mucins are released in extracellular space and can be found and measured in serum and other biological fluids. Among mucins, CA 19.9 is widely used for diagnosing gastrointestinal cancers (1), CA 125 for gynecological cancers (2), and CA 15.3 for breast cancer (3). Despite the wide use of these tumor markers in clinical laboratories, few data about their preanalytical phase exist.

We studied the stability of CA19.9, CA 125, and CA 15.3 for 72 h and the effect of serum collection differences between plain tubes and tubes with thixotropic gel. We used our findings to define practical and empirical guidelines for blood drawing, storage, transportation, and delay from venipuncture to analysis.

We collected blood by routine sampling, namely, in plain tubes (pink cap, 7-mL Vacutainer Tube; Becton Dickinson) and in gel-containing tubes (gold cap, 5-mL Vacutainer Tube), completely filling the tubes and centrifuging them at 4 °C . . . [Full Text of this Article]


Footnotes


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.